US pauses distribution of GSK/Vir's Covid mAb not due to Omicron, but greater supply of Eli Lilly mAbs

The US government is shifting its distribution of mAb infusions to fight the coronavirus, deciding to go from supplying tens of thousands of doses of GlaxoSmithKline and Vir’s mAb treatment sotrovimab in recent months to zero doses for the entire month of December.